LINCOLN · NSE
Lincoln Pharmaceuticals Limited
₹604.85
+0.69% (+₹4.15)
Prev. close
₹600.7
Volume
18,250
Delivery %
53.4%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, anti-infective, anti-bacterial, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics in the form of tablets, capsules, injectables, dry syrups, sprays, ointments etc. It exports its products to Europe, Canada, Latin and North America, Africa, Asia, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mahendrabhai Gulabdas Patel B.A, LLB
Headquarters
Ahmedabad
Employees
1,352
Website
lincolnpharma.comExchange
View on NSE ↗Key stats
Market cap
₹1,211.50 Cr
P/E ratio (TTM)
12.6
Dividend yield
0.30%
EPS (TTM)
₹48.18
Beta (1Y · daily vs NIFTY 50)
0.66
Beta (5Y · monthly vs NIFTY 50)
0.91
Shares float
92.65 L
EPS · quarter ended Jun 2026
₹18.09
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹413.06 Cr | ₹472.08 Cr | ₹510.31 Cr | ₹580.55 Cr | ₹623.23 Cr | ₹671.03 Cr | |
| EBITDA | — | ₹105.48 Cr | ₹111.68 Cr | ₹134.33 Cr | ₹123.97 Cr | ₹131.14 Cr |
| ₹60.41 Cr | ₹69.00 Cr | ₹72.90 Cr | ₹93.30 Cr | ₹82.35 Cr | ₹87.89 Cr | |
| Diluted EPS | ₹30.2 | ₹34.63 | ₹36.4 | ₹46.58 | ₹41.11 | ₹43.88 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, EBITDA, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹452.00 Cr | ₹534.00 Cr | ₹587.00 Cr | ₹700.00 Cr | ₹797.00 Cr | ₹890.00 Cr | |
| ₹51.97 L | ₹2.04 Cr | ₹2.00 Cr | ₹1.07 Cr | — | ₹4.42 Cr | |
| Stockholders' equity | ₹366.00 Cr | ₹433.00 Cr | ₹502.00 Cr | ₹593.00 Cr | ₹672.00 Cr | ₹758.00 Cr |
Current assets, Trade receivables, Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹69.00 Cr | ₹76.00 Cr | ₹39.00 Cr | ₹63.00 Cr | ₹93.00 Cr | ₹106.00 Cr | |
| Investing cash flow | ₹-64.91 Cr | — | ₹-36.64 Cr | ₹-57.34 Cr | ₹-78.95 Cr | ₹-98.40 Cr |
| ₹-5.30 Cr | — | ₹-4.50 Cr | ₹-5.18 Cr | ₹-6.40 Cr | ₹15.89 L | |
| Capital expenditure | ₹-8.28 Cr | — | ₹-14.28 Cr | ₹-39.61 Cr | ₹-19.24 Cr | ₹-26.04 Cr |
| End cash position | ₹10.13 Cr | — | ₹5.05 Cr | ₹5.75 Cr | ₹13.41 Cr | ₹21.53 Cr |
Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 15 | Mar 16–Jun 16(2Q) | Sep 16 | Oct 16–Dec 16(2Q) | Mar 17–Jun 17(2Q) | Sep 17 | Dec 17 | Mar 18 | Jun 18–Dec 19(7Q) | Mar 20–Jun 20(2Q) | Sep 20 | Dec 20 | Mar 21 | Jun 21 | Sep 21 | Dec 21 | Mar 22 | Jun 22–Sep 22(2Q) | Dec 22 | Mar 23 | Jun 23 | Sep 23–Dec 23(2Q) | Mar 24 | Jun 24–Jun 26(9Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 34.97% | 34.93% | 34.91% | 32.47% | 32.46% | 32.47% | 32.72% | 31.43% | 31.68% | 31.63% | 31.68% | 32.68% | 37.26% | 37.06% | 39.55% | 41.28% | 41.32% | 43.36% | 45.61% | 46.28% | 47.95% | 49.80% | 49.53% | 49.78% |
| Public | 65.03% | 65.07% | 65.09% | 67.53% | 67.54% | 67.53% | 67.28% | 68.57% | 68.32% | 68.37% | 68.32% | 67.32% | 62.74% | 62.94% | 60.45% | 58.72% | 58.68% | 56.64% | 54.39% | 53.72% | 52.05% | 50.20% | 50.47% | 50.22% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Lincoln Pharmaceuticals Limited | ₹1,183.16 Cr | ₹600.7 | 12.3 | 1.56 | 11.6% | 0.01 | +7.7% | +8.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.